S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:ICLR - Icon Stock Price, Forecast & News

$160.46
-3.11 (-1.90 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$158.39
Now: $160.46
$164.54
50-Day Range
$160.46
MA: $171.76
$177.22
52-Week Range
$127.58
Now: $160.46
$178.99
Volume346,322 shs
Average Volume217,678 shs
Market Capitalization$8.66 billion
P/E Ratio23.60
Dividend YieldN/A
Beta0.77
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.81 billion
Cash Flow$7.57 per share
Book Value$25.09 per share

Profitability

Net Income$373.99 million

Miscellaneous

Employees13,670
Market Cap$8.66 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.


Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) posted its quarterly earnings data on Wednesday, February, 19th. The medical research company reported $1.83 earnings per share for the quarter, meeting analysts' consensus estimates of $1.83. The medical research company earned $725.40 million during the quarter, compared to analysts' expectations of $734.13 million. Icon had a net margin of 13.33% and a return on equity of 25.00%. The firm's revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.62 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY20 earnings guidance on Wednesday, February, 19th. The company provided EPS guidance of $7.55-7.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.71. The company issued revenue guidance of $2.972-3.092 billion, compared to the consensus revenue estimate of $3.04 billion.

What price target have analysts set for ICLR?

9 brokerages have issued 12 month price objectives for Icon's shares. Their forecasts range from $160.00 to $194.00. On average, they expect Icon's stock price to reach $178.75 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

News articles about ICLR stock have trended somewhat positive on Tuesday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Icon earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Icon.

Are investors shorting Icon?

Icon saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,180,000 shares, an increase of 16.8% from the December 31st total of 1,010,000 shares. Based on an average trading volume of 254,500 shares, the days-to-cover ratio is currently 4.6 days. Approximately 2.2% of the company's shares are short sold. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), Procter & Gamble (PG), Post (POST), Visa (V), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and Amgen (AMGN).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a number of of institutional and retail investors. Top institutional investors include WCM Investment Management LLC (6.75%), Renaissance Technologies LLC (4.35%), Alliancebernstein L.P. (3.93%), Acadian Asset Management LLC (3.91%), Earnest Partners LLC (3.80%) and Comgest Global Investors S.A.S. (3.26%).

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Janus Henderson Group PLC, Bank of New York Mellon Corp, Lord Abbett & CO. LLC, FMR LLC, PNC Financial Services Group Inc., Principal Financial Group Inc. and Alliancebernstein L.P..

Which institutional investors are buying Icon stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Comgest Global Investors S.A.S., Massachusetts Financial Services Co. MA, FIL Ltd, Man Group plc, WCM Investment Management LLC, Knights of Columbus Asset Advisors LLC and Polen Capital Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $160.46.

How big of a company is Icon?

Icon has a market capitalization of $8.66 billion and generates $2.81 billion in revenue each year. The medical research company earns $373.99 million in net income (profit) each year or $6.88 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com/.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  523 (Vote Outperform)
Underperform Votes:  482 (Vote Underperform)
Total Votes:  1,005
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel